Evogene Ltd.
EVGN
$0.97
-$0.0255-2.56%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 236.72% | 331.52% | 331.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 236.72% | 331.52% | 331.52% |
| Cost of Revenue | -- | -- | 86.14% | 104.19% | 104.19% |
| Gross Profit | -- | -- | 415.40% | 690.66% | 690.66% |
| SG&A Expenses | -- | -- | -7.07% | -0.67% | -0.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 12.34% | -14.45% | -14.45% |
| Operating Income | -- | -- | 1.61% | 28.85% | 28.85% |
| Income Before Tax | -- | -- | 12.66% | 34.18% | 34.18% |
| Income Tax Expenses | -- | -- | -136.67% | -58.97% | -58.97% |
| Earnings from Continuing Operations | -- | -- | 13.03% | 34.21% | 34.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -35.28% | -30.17% | -30.17% |
| Net Income | -- | -- | 10.36% | 34.62% | 34.62% |
| EBIT | -- | -- | 1.61% | 28.85% | 28.85% |
| EBITDA | -- | -- | 1.91% | 31.63% | 31.63% |
| EPS Basic | -- | -- | 17.75% | 37.05% | 37.05% |
| Normalized Basic EPS | -- | -- | 7.86% | 45.84% | 45.84% |
| EPS Diluted | -- | -- | 17.75% | 37.05% | 37.05% |
| Normalized Diluted EPS | -- | -- | 7.86% | 45.84% | 45.84% |
| Average Basic Shares Outstanding | -- | -- | 10.80% | 5.17% | 5.17% |
| Average Diluted Shares Outstanding | -- | -- | 10.80% | 5.17% | 5.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |